Evaluate Harm Reduction Products as a Second Line Intervention for Adult Smokers Who Do Not Quit With NRT

• Nicoderm (Drug), also known as Nicotine Patch: 21mg nicotine patch daily; maximum usage 9 weeks
• Nicorette 4Mg Chewing Gum (Drug), also known as Nicotine gum: 4mg Nicorette gum (flavors - cinnamon surge, fruit chill, and mint); as needed maximum usage 9 weeks
• Nicorette Lozenge Product (Drug), also known as Nicotine lozenge: 4mg Nicorette mint lozenge; as needed maximum usage 9 weeks
• BIDI e-cigarette (Other): BIDI e-cigarette (flavors - Classic, Arctic, and Solar); as needed for maximum of 5 weeks
• on! (Other), also known as Nicotine pouch: 4mg on! Nicotine Pouch (flavors - Berry, Mint, and Original); as needed for maximum usage 5 weeks

Primary outcomes

• Change in smoke exposure for NRT non-responders [After 10 weeks]: Change in expired air CO at week 10 compared to baseline

Secondary outcomes

• Smoking abstinence rates for NRT non-responders [Week 7 - Week 10]: Complete smoking abstinence defined by a self-report of no cigarette smoking (not even a puff).
• Smoking abstinence rates for NRT non-responders [Week 7 - Week 10]: Complete smoking abstinence defined by expired air CO<6 ppm.

Sex: All, ages: 22 Years to 65 Years, accepts healthy volunteers

Inclusion Criteria:

1. Has signed the Informed Consent From (ICF) and is able to read and understand the information provided in the ICF.
2. Is 22 to 65 years of age (inclusive) at screening.
3. Smokes an average of at least 10 commercially available cigarettes per day and has done so for the last 12 months.
4. Expired air CO reading of at least 10 ppm as assessed at the screening session.
5. Interested in switching to an electronic cigarette or nicotine pouch.
6. Willing and able to comply with the requirements of the study.
7. Owns a smart phone with text message and data capabilities compatible with necessary surveys.

Exclusion Criteria:

1. Any participant who has a medical or physical condition that, in the opinion of the investigator (or designee), may adversely affect participant safety, the safety of others, or data validity.
2. Planned use of an FDA-approved smoking cessation product during the study, not provided as part of this protocol.
3. Coronary heart disease, structural cardiac disease (including, but not limited to valvular heart disease or cardiac murmurs), cardiac dysrhythmias, syncope, cardiac chest pain, or history of heart attack or heart failure.
4. Taking psychoactive medications (e.g., antipsychotics, benzodiazepines, or mood stabilizers).
5. Frequent users (monthly) of smokeless tobacco (chewing tobacco, snuff), cigars (not cigarillos), pipes, hookahs or other non-commercially available combustible or heated tobacco products.
6. Use of nicotine replacement therapy or other smoking cessation treatments within 14 days of screening.
7. Pregnant or nursing (by self-report) or positive pregnancy test.
8. Heterosexually active participant of Childbearing Potential (not sterilized by tubal ligation, oophorectomy, hysterectomy, or other surgical methods, or post-menopausal) that do not agree to practice medically appropriate methods of birth control (or remain abstinent) during the course of the trial. Medically acceptable methods of birth control include: successful vasectomy of male partner, vaginal diaphragm with spermicide, intrauterine device, hormonal birth control (oral, injected, or implanted), condom with spermicide, or sponge with spermicide.
9. Participants who were enrolled in a clinical trial within 30 days of screening.
10. Enrollment numbers met (in sub-group or entire study).